Table 2.
Validated Mutations and PTEN Loss Detected by Histological Subtype
| Gene | Total (N=80) | Squamous cell carcinoma (SCC) (N=40) |
Adenocarcinoma (AC) (N=40) |
P-value |
|---|---|---|---|---|
| Any PIK3CA mutation1 | 25 (31.3) | 15 (37.5) | 10 (25.0) | 0.33 |
| E542K | 10 (12.5) | 6 (15.0) | 4 (10.0) | |
| E545K | 16 (20.0) | 10 (25.0) | 6 (15.0) | |
| E453K | 1 (1.3) | 0 (0.0) | 1 (2.5) | |
| 3R88Q | 1 (1.3) | 0 (0.0) | 1 (2.5) | |
| Any KRAS mutation | 7 (8.8) | 0 (0.0) | 7 (17.5) | 0.01 |
| G12A | 1 (1.3) | 0 (0.0) | 1 (2.5) | |
| G12D | 3 (3.8) | 0 (0.0) | 3 (7.5) | |
| G12V | 2 (2.5) | 0 (0.0) | 2 (5.0) | |
| G13D | 1 (1.3) | 0 (0.0) | 1 (2.5) | |
| EGFR mutation2 | 3 (3.8) | 3 (7.5) | 0 (0.0) | 0.24 |
| Any PTEN loss3 | 4 (7.8) | 3 (13.0) | 1 (3.6) | 0.32 |
1
3/80 (3.8%) of samples had combined PIK3CA mutations (e.g., E542K and E545K).
2
Two additional squamous cell carcinomas had EGFR S703F detected with hME chemistry or Illumina sequencing.
3
51 samples were available for immunohistochemistry to detect PTEN loss (28 AC and 23 SCC).